fda warning letter hims & hers compounded semaglutide september 2025 There's lots going on this month at in the world of weight loss drugs. The agency is taking a hard look at the market. Check out these new #FDA Letters Hims & Hers stock crashes

CrossRef Association of four insulin resistance indices with liverrelated adverse outcomes: A prospective cohort study XiaoMeng Wang, Hao Yan, WenFang Zhong, JiaHao Xie, Huan Chen, JunJie Wang, WeiQi Song, Dong Shen, PeiDong Zhang, XiRu Zhang, JiaoJiao Ren, Dan Liu, ZhiHao Li, Chen Mao Diabetes, Obesity and Metabolism .2026

And make no mistake: this is part of a bigger push

Researchers frequently compare semaglutide or tirzepatide and, like Ozempic-class compounds, it acts on incretin signalling rather than a single receptor

The article says no large randomized controlled trials have evaluated GLP-1 agonists as primary RA therapeutics, and its evidence table lists that category as none published to date

Directions Recommended dose: 1 capsule per day